avn-211 avn-211 avn-211 (cd-008-0173) is a drug which acts as a highly selective 5-ht6 receptor antagonist and is under development by avineuro pharmaceuticals for the treatment of schizophrenia. in early 2011, it successfully completed phase iia clinical trials, with benefits on positive symptoms and some procognitive effects observed, and in mid 2013, phase iib clinical trials for schizophrenia began. avineuro pharmaceuticals also expressed intention to start clinical trials of avn-211 for alzheimer's disease in 2015. avn-211clinical dataother namescd-008-0173identifiers iupac name 5,7-dimethyl-2-(methylsulfanyl)-3-(phenylsulfonyl)pyrazolopyrimidine cas number1173103-84-8chemspider26387125chemblchembl1668500chemical and physical dataformulac15h15n3o2s2molar mass333.42 g·mol−13d model (jsmol)interactive image smiles cc1cc(n2c(n1)c(c(n2)sc)s(=o)(=o)c3ccccc3)c inchi inchi=1s/c15h15n3o2s2/c1-10-9-11(2)18-14(16-10)13(15(17-18)21-3)22(19,20)12-7-5-4-6-8-12/h4-9h,1-3h3key:ksaucbguwgwpdl-uhfffaoysa-n